Astellas Pharma

Astellas Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Astellas Pharma (4503.T) as of Nov 13, 2026 is 9.22. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 31.31 — a change of -70.55% (lower).

EV/FCF

9.22

YoY

-70.55%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Astellas Pharma is 2026 9.22 . EV/FCF (Enterprise Value to Free Cash Flow) of Astellas Pharma was 2025 31.31 . It decreases by -70.55% lower compared to the previous year.

The Astellas Pharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
17.55 JPY
Jan 1, 2020
31.58 JPY
Jan 1, 2021
19.00 JPY
Jan 1, 2022
23.77 JPY
Jan 1, 2023
17.68 JPY
Jan 1, 2024
35.43 JPY
Jan 1, 2025
31.31 JPY
Jan 1, 2026
9.22 JPY
The Astellas Pharma EV/FCF history
YEAREV/FCFYoY
9.22-70.55%
31.31-11.62%
35.43+100.42%
17.68-25.64%
23.77+25.13%
19.00-39.85%
31.58+79.98%
17.55+24.60%
14.08-27.89%
19.53+36.58%
14.30-40.88%
24.18+13.42%
21.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Astellas Pharma Stock analysis

What does Astellas Pharma do? Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Astellas Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Astellas Pharma is 9.22 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Astellas Pharma changed from 31.31 to 9.22, representing a -70.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Astellas Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Astellas Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Astellas Pharma

All Key Metrics — Astellas Pharma